Press Releases

Press Releases

Date Title
07/29/21 Vaxart Reports Boosting Immune Responses in Subjects Previously Vaccinated by a Vaxart Vaccine
First booster clinical study by Vaxart shows boosted immune responses similar to original responses with Vaxart vaccine Findings have potential implications for Vaxart's COVID-19 oral vaccine program SOUTH SAN FRANCISCO, Calif. , July 29, 2021 /PRNewswire/ --  Vaxart, Inc.
07/07/21 Vaxart Announces Exclusive Worldwide License Agreement with Altesa Biosciences for its Vapendavir Antiviral Asset
Milestone payments up to $130 million and royalties for global Vapendavir sales Vapendavir has demonstrated activity against a broad spectrum of enteroviruses SOUTH SAN FRANCISCO, Calif. , July 07, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company
06/07/21 Vaxart to Present at the SVB Leerink CybeRx Series: Vaccine Forum
SOUTH SAN FRANCISCO, Calif. , June 07, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that its executive officers, Andrei Floroiu , CEO, and
05/27/21 Vaxart to Present at the Jefferies Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , May 27, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Andrei Floroiu , CEO and Sean Tucker , CSO of the
05/07/21 Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Dose-Ranging Trial in Elderly Adults
Study will evaluate safety and immunogenicity of oral norovirus vaccine in elderly population Norovirus represents a significant unmet need in the elderly — there currently is no approved vaccine Safety and immunogenicity data to also inform oral COVID-19 vaccine program in older population SOUTH
05/04/21 Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Boosting Regimen Study
Study will evaluate safety and immunogenicity of multiple distinct dosing regimens of norovirus oral vaccine candidate Norovirus infects 15% of U.S. children under age five every year Study results may inform the COVID-19 oral vaccine program SOUTH SAN FRANCISCO, Calif.
05/03/21 New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses
Vaxart oral vaccine induced higher CD8 +   T-Cell responses than those seen with  Moderna or Pfizer vaccines in comparative experiment conducted by the Company IgA antibodies triggered in the mucosa, show broad cross-reactivity SOUTH SAN FRANCISCO, Calif.
05/03/21 Vaxart Reports First Quarter 2021 Financial Results and Provides Business Update
Vaxart to advance three oral tablet COVID-19 vaccine candidates to the clinic: VXA-CoV2-1 (includes both the S and the N proteins) into Phase II and two S-only constructs into Phase I/II Four clinical trials of the oral norovirus vaccine candidate to be initiated in 2021 Cash, cash equivalents, and
04/29/21 Vaxart to Present at the World Vaccine Congress Washington 2021
SOUTH SAN FRANCISCO, Calif. , April 29, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that its founder and chief scientific officer, Sean
04/26/21 Vaxart to Host a Key Opinion Leader Webinar on the Importance of T-Cell Responses for COVID-19 Vaccines
Vaxart to provide new data from its Phase I COVID-19 trial Stanford University T-cell expert to discuss cross-protection against variants SOUTH SAN FRANCISCO, Calif. , April 26, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant